Influenza vaccine containing a recombinant, antigenically hybrid

Details Influenza vaccine containing a recombinant, antigenically hybrid Influenza vaccine containing a recombinant, antigenically hybrid

1974-08-05

1977-02-22

Rosen, Sam

Drug, bio-affecting and body treating compositions

Lymphokine

195 11, 195 12, 195 18, A61K 3912, C12K 500, C12K 700

Patent

active

040092585

ABSTRACT:
An influenza vaccine is disclosed which comprises, as an active ingredient, a recombinant, antigenically hydridized virus which has a hemagglutinin antigen that has substantially no cross-reactivity with those influenza viruses against which the vaccine is to be effective and a neuraminidase antigen which has substantial cross-reactivity with the influenza viruses against which the vaccine is to be effective. The neuraminidase can be derived from a virus antigenically representative of the contemporary or prevalent influenza virus of interest, e.g., H3N3, the Hong Kong variant of influenza, while the hemagglutinin antigen, in a preferred embodiment of the invention, is obtained from A-1/equine virus or from other influenza viruses of other antigenic subtypes, such as HON1 or H1N1.

REFERENCES:
kilbourne-Science, vol. 160, Apr. 1968, pp. 74 and 75.
Schulman et al.-Proc. National Acad. of Science-vol. 63, No. 2, pp. 326-3 3.

Affiliated with

Also associated with

Rating

Influenza vaccine containing a recombinant, antigenically hybrid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza vaccine containing a recombinant, antigenically hybrid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza vaccine containing a recombinant, antigenically hybrid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-324346